FY2027 Earnings Estimate for Q32 Bio Issued By HC Wainwright

Q32 Bio Inc. (NASDAQ:QTTB) – Research analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Q32 Bio in a report released on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.54) per share for the year, up from their prior estimate of ($2.00). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.54) per share.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.02.

QTTB has been the topic of several other research reports. Morgan Stanley assumed coverage on shares of Q32 Bio in a report on Monday, August 24th. They issued an “overweight” rating and a $34.00 price target on the stock. Jefferies Financial Group assumed coverage on Q32 Bio in a research report on Monday, September 28th. They set a “buy” rating and a $29.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating on shares of Q32 Bio in a research note on Thursday. Mizuho upgraded Q32 Bio to a “strong-buy” rating in a report on Monday, September 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Q32 Bio in a research report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Q32 Bio presently has a consensus rating of “Moderate Buy” and an average target price of $30.60.

Q32 Bio Trading Down 0.2%

NASDAQ:QTTB opened at $8.23 on Friday. The firm has a 50-day moving average price of $13.26 and a two-hundred day moving average price of $10.77. Q32 Bio has a twelve month low of $1.90 and a twelve month high of $23.57. The company has a market capitalization of $245.01 million, a P/E ratio of 2.74 and a beta of 0.31.

Insider Transactions at Q32 Bio

In other news, insider Shelia Violette sold 2,798 shares of Q32 Bio stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $46,334.88. Following the completion of the sale, the insider directly owned 127,771 shares in the company, valued at $2,115,887.76. The trade was a 2.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Lee Kalowski sold 3,972 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer directly owned 138,471 shares in the company, valued at $2,293,079.76. The trade was a 2.79% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,615 shares of company stock worth $275,144 over the last ninety days. 34.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new stake in shares of Q32 Bio in the second quarter valued at $303,000. Atlas Venture Life Science Advisors LLC boosted its stake in Q32 Bio by 29.9% in the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock worth $34,616,000 after buying an additional 625,000 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Q32 Bio in the 2nd quarter worth about $297,000. Carlyle Group Inc. purchased a new stake in Q32 Bio in the 2nd quarter valued at about $769,000. Finally, BlackRock Inc. acquired a new position in shares of Q32 Bio during the 2nd quarter valued at about $1,510,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with immune dysregulation. The company’s research is aimed at restoring balance in the immune system by targeting biological pathways involved in inflammation, tissue repair and immune regulation.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to inhibit activin A signaling through the activin receptor type IIB pathway.